Wellington Management Group LLP Purchases 2,222,900 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Wellington Management Group LLP increased its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 2,410.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,315,123 shares of the company's stock after buying an additional 2,222,900 shares during the period. Wellington Management Group LLP owned 2.51% of NewAmsterdam Pharma worth $59,499,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NAMS. Jennison Associates LLC raised its position in shares of NewAmsterdam Pharma by 291.9% in the fourth quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after buying an additional 2,978,263 shares in the last quarter. TimesSquare Capital Management LLC raised its position in NewAmsterdam Pharma by 250.9% during the fourth quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company's stock valued at $23,016,000 after purchasing an additional 640,329 shares in the last quarter. Frazier Life Sciences Management L.P. raised its position in NewAmsterdam Pharma by 5.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company's stock valued at $213,396,000 after purchasing an additional 628,251 shares in the last quarter. Janus Henderson Group PLC raised its position in NewAmsterdam Pharma by 51.1% during the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company's stock valued at $25,607,000 after purchasing an additional 520,772 shares in the last quarter. Finally, American Century Companies Inc. acquired a new position in NewAmsterdam Pharma during the fourth quarter valued at approximately $8,907,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other NewAmsterdam Pharma news, Director James N. Topper bought 1,135 shares of the stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the acquisition, the director now directly owns 3,013,569 shares of the company's stock, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. This represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. 19.50% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ NAMS traded down $1.12 during trading on Thursday, hitting $14.75. 85,323 shares of the company traded hands, compared to its average volume of 577,758. The business's fifty day moving average is $20.51 and its 200 day moving average is $21.26. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -5.66 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. On average, analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Royal Bank of Canada restated an "outperform" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Scotiabank boosted their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, NewAmsterdam Pharma has an average rating of "Buy" and an average price target of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.